- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01180010
Low Dose Chest Computed Tomography (CT) Screening
December 28, 2016 updated by: University Health Network, Toronto
Low-Dose Chest CT for Lung Cancer Screening in Survivors of Hodgkin's Disease
This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment.
The risk appears to be further increased among patients with a smoking history.
In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.
Depending on the findings of the initial CT scan, we will then either repeat the scan in 1 year, or if indicated, send you for further scans or a biopsy.
The information collected in this study will help researchers and clinicians in providing more concrete recommendations and screening guidelines for future survivors of Hodgkin's disease who have had similar exposures to radiation and/or chemotherapy and smoking.
Study Overview
Study Type
Observational
Enrollment (Actual)
31
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network, Princess Margaret Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients treated for Hodgkin's Lymphoma
Description
Inclusion Criteria:
- 5 years or longer from initial Hodgkin's disease diagnosis
- Current age 18 or older
- Received mediastinal irradiation and/or alkylating-agent based chemotherapy
- Smoking history of 10-pack years or more, or current smoker
Exclusion Criteria:
- Patients with a history of lung cancer
- Patients currently receiving treatment for another cancer diagnosis (patients with another cancer, but currently disease-free and not receiving treatment are eligible)
- Patients with known diagnosis of any metastatic cancer
- Pregnant women. Female patients must: be at least one year post-menopausal, have had a hysterectomy, or have a serum pregnancy test to confirm that they are not pregnant. These measures must be taken in order to avoid doing a CT scan of a pregnant woman.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lung cancer detection rate using chest CT screening in patients at increased risk of lung cancer after Hodgkin's disease therapy.
Time Frame: 5 years
|
5 years
|
False-positive rates of using chest CT for lung cancer screening in this population.
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The stage distribution, clinical characteristics and pathologic features of the detected lung cancer
Time Frame: 5 years
|
5 years
|
The treatment and treatment outcome of lung cancer after Hodgkin's disease in a cohort of patients undergoing routine chest CT screening
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: David Hodgson, MD, University Health Network, Princess Margaret Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
August 10, 2010
First Submitted That Met QC Criteria
August 10, 2010
First Posted (Estimate)
August 11, 2010
Study Record Updates
Last Update Posted (Estimate)
December 29, 2016
Last Update Submitted That Met QC Criteria
December 28, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHN REB 08-0294-CE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Lymphoma
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
-
Western Regional Medical CenterWithdrawnLymphoma | Hodgkin's Lymphoma | Non-hodgkin's LymphomaUnited States
-
West Virginia UniversityCompletedHodgkin's Lymphoma | Non-Hodgkin's LymphomaUnited States
Clinical Trials on Low Dose CT
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Sang-Won UmNot yet recruitingHealth Risk Behaviors
-
University Hospital, GenevaCompleted
-
Oncology Teaching Hospital, BaghdadEnrolling by invitation
-
The University of QueenslandActive, not recruitingNeoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Non-small Cell Lung Cancer | Smokers at Risk of Lung CancerAustralia, Canada
-
Oslo University HospitalOdense University HospitalCompletedAbdominal Pain | Acute Pain | Acute Pancreatitis | Acute Cholecystitis | Acute AppendicitisNorway, Denmark
-
University Health Network, TorontoCompleted
-
Hospices Civils de LyonCompletedTelangiectasia, Hereditary Hemorrhagic | Rendu Osler DiseaseFrance